Alnylam Makes Entry Into Chinese RNAi Market

Chinese small interfering siRNA supplier Shangahi GenePharma has acquired a nonexclusive worldwide license to Alnylam Pharmaceuticals' Kreutzer-Limmer patent group, which is the first business transaction in China made by the Cambridge, Mass.-based RNAi firm

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip